FDA grants priority review for drug to treat APLSeptember 14, 2017Leukemia, Myelodysplasia, TransplantationPharmacy
R&D costs for cancer drugs may be lower than previously thoughtSeptember 13, 2017PharmacyRelated Issues
Withdrawn AML drug back on market in USSeptember 2, 2017Leukemia, Myelodysplasia, TransplantationPediatricsPharmacyAML
TKI granted priority review for newly diagnosed CMLAugust 30, 2017Leukemia, Myelodysplasia, TransplantationPharmacyCML
Drug receives priority review for FLAugust 29, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Drug granted breakthrough designation for CTCLAugust 26, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
Drug granted orphan designation for chemo-induced ototoxicityAugust 23, 2017Lymphoma & Plasma Cell DisordersPediatricsPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
FDA grants drug orphan designation for AMLAugust 22, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
FDA approves inotuzumab ozogamicin for rel/ref ALLAugust 18, 2017Leukemia, Myelodysplasia, TransplantationPharmacyALL
Post-approval trials for accelerated drugs fall shortAugust 16, 2017AnemiaLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaPharmacy